Literature DB >> 10210143

Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection.

T Martin1, S E Parker, R Hedstrom, T Le, S L Hoffman, J Norman, P Hobart, D Lew.   

Abstract

Plasmid-based (naked DNA) genetic vaccines are now entering clinical trials to test their safety and efficacy in healthy human volunteers. A safety concern unique to this new class of vaccines is the potential risk of deleterious integration into host cell genomic DNA following direct intramuscular injection. To address this issue experimentally, a preclinical safety study was conducted in mice to determine the structural nature of plasmid DNA sequences persisting in total muscle DNA at both 30 and 60 days following a single intramuscular injection of a plasmid expressing the Plasmodium falciparum circumsporozoite protein. In a protocol described for the first time, total DNA was extracted from muscle tissue and was subsequently linearized with a restriction endonuclease to enable agarose gel size fractionation of all extrachromosomal plasmid DNAs from high molecular weight mouse genomic DNA. Using PCR assays to quantitate plasmid-specific sequences, it was found that the amount of plasmid DNA persisting in muscle tissue varied but averaged about 10 fg per microgram of genomic DNA (in the range of 1500 copies per 150,000 genomes). In two of four separate experimental injections of mouse muscle, PCR assays of genomic DNA fractions indicated that agarose gel purification removed plasmid DNA down to a level of < or =3 copies per 150,000 mouse genomes. In the two other experimental samples, 3-30 copies of plasmid DNA remained associated with purified genomic DNA. The time following injection (i.e., 30 or 60 days) was not a factor in the number of copies of plasmid associating with genomic DNA and it was not possible to conclude if such sequences were covalently linked to genomic DNA or simply adventitiously associated with the genomic DNA. However, if an assumption is made that the highest level plasmid DNA found associated with genomic DNA (i.e., 30 copies) represented covalently integrated plasmid inserts and that each insert resulted in a mutational event, the calculated rate of mutation would be 3000 times less than the spontaneous mutation rate for mammalian genomes. This level of integration, if it should occur, was not considered to pose a significant safety concern.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10210143     DOI: 10.1089/10430349950018517

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  32 in total

1.  Genetic fate of recombinant adeno-associated virus vector genomes in muscle.

Authors:  Bruce C Schnepp; K Reed Clark; Dori L Klemanski; Christina A Pacak; Philip R Johnson
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  Analysis of DNA-vaccinated fish reveals viral antigen in muscle, kidney and thymus, and transient histopathologic changes.

Authors:  Kyle A Garver; Carla M Conway; Diane G Elliott; Gael Kurath
Journal:  Mar Biotechnol (NY)       Date:  2005-07-22       Impact factor: 3.619

3.  Pharmacokinetics and risk evaluation of DNA vaccine against Schistosoma japonicum.

Authors:  Hai-Feng Liu; Wei Li; Ming-Bo Lu; Long-Jiang Yu
Journal:  Parasitol Res       Date:  2012-09-19       Impact factor: 2.289

4.  Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine.

Authors:  Jian Yan; Daniel O Villarreal; Trina Racine; Jaemi S Chu; Jewell N Walters; Matthew P Morrow; Amir S Khan; Niranjan Y Sardesai; J Joseph Kim; Gary P Kobinger; David B Weiner
Journal:  Vaccine       Date:  2014-03-12       Impact factor: 3.641

Review 5.  Latest developments and future directions in dengue vaccines.

Authors:  Usa Thisyakorn; Chule Thisyakorn
Journal:  Ther Adv Vaccines       Date:  2014-01

Review 6.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

7.  Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques.

Authors:  Jian Yan; Kristina Harris; Amir S Khan; Ruxandra Draghia-Akli; Duane Sewell; David B Weiner
Journal:  Vaccine       Date:  2008-04-14       Impact factor: 3.641

Review 8.  FDA guidance on prophylactic DNA vaccines: analysis and recommendations.

Authors:  Dennis M Klinman; Sven Klaschik; Debra Tross; Hidekazu Shirota; Folkert Steinhagen
Journal:  Vaccine       Date:  2009-11-24       Impact factor: 3.641

9.  Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine.

Authors:  Krystle A Lang; Jian Yan; Ruxandra Draghia-Akli; Amir Khan; David B Weiner
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

10.  Prospects for control of emerging infectious diseases with plasmid DNA vaccines.

Authors:  Ronald B Moss
Journal:  J Immune Based Ther Vaccines       Date:  2009-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.